The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Solazyme's revenues will contract -3.2% and EPS will remain in the red.
The average estimate for revenue is $8.6 million. On the bottom line, the average EPS estimate is -$0.35.
Last quarter, Solazyme booked revenue of $13.5 million. GAAP reported sales were 83% higher than the prior-year quarter's $7.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.27. GAAP EPS were -$0.32 for Q2 against -$0.61 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 90.2%, 470 basis points worse than the prior-year quarter. Operating margin was -146.8%, 3,710 basis points better than the prior-year quarter. Net margin was -142.0%, 8,700 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $47.2 million. The average EPS estimate is -$1.23.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 335 members out of 356 rating the stock outperform, and 21 members rating it underperform. Among 66 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give Solazyme a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Solazyme is outperform, with an average price target of $18.50.
Are you missing a major story in the energy space? Read about "One Stock to Own Before Nat Gas Act 2011 Becomes Law." Click here for instant access to this free report.
- Add Solazyme to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Solazyme. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.